Masaya Murakami

发表

Oncological outcomes of a multicenter cohort treated with axitinib for metastatic renal cell carcinoma

H. Nishiyama, S. Anai, A. Yokomizo, 2020, Cancer science.

Clinical efficacy and prognostic factors of tumor progression in Japanese patients with advanced renal cell carcinoma treated with sorafenib.

H. Kume, N. Kawata, M. Oya, 2015, Japanese journal of clinical oncology.

Efficacy and safety of second-line axitinib in octogenarians with metastatic renal cell carcinoma.

H. Nishiyama, A. Takeuchi, Yoshiaki Yamamoto, 2020, Journal of geriatric oncology.

Outcomes of laparoscopic resection of urachal remnants followed by novel umbilicoplasty

S. Egawa, H. Sasaki, S. Kimura, 2018, International Urology and Nephrology.

Novel technique to secure closure of the umbilical defect and umbilical reconstruction after laparoscopic resection of urachal remnant

S. Egawa, H. Sasaki, Shunsuke Tsuzuki, 2020, International journal of urology : official journal of the Japanese Urological Association.

[Six cases of renal collecting duct carcinoma].

S. Egawa, N. Furuta, J. Miki, 2014, Hinyokika kiyo. Acta urologica Japonica.

Prognostic model with alkaline phosphatase, lactate dehydrogenase and presence of Gleason pattern 5 for worse overall survival in low-risk metastatic hormone-sensitive prostate cancer.

S. Egawa, Shunsuke Tsuzuki, Masayuki Tomita, 2021, Japanese journal of clinical oncology.

Low Body Weight as a Risk Factor for Apalutamide-related Cutaneous Adverse Events

S. Egawa, Toshihiro Yamamoto, A. Asahina, 2022, AntiCancer Research.

Radiographic Progression at Castration-Resistant Prostate Cancer Diagnosis: A Prognostic Indicator of Metastatic Hormone-Sensitive Prostate Cancer.

Shunsuke Tsuzuki, K. Mori, Fumihiko Urabe, 2024, Clinical genitourinary cancer.

Abiraterone Acetate Versus Enzalutamide Against Chemo-Naïve Castration-Resistant Prostate Cancer With Full-Dose Induction

K. Mori, Fumihiko Urabe, T. Yanagisawa, 2024, Cureus.

Docetaxel versus androgen receptor signaling inhibitor (ARSI) against chemo-naïve castration-resistant prostate cancer (CRPC): propensity score matched analysis in real world.

K. Mori, Kagenori Ito, Yusuke Koike, 2024, International urology and nephrology.

Survival outcome of chemotherapy-naïve castration-resistant prostate cancer treated with new-generation androgen receptor axis-targeted agents in real-world analysis

K. Mori, Yusuke Koike, J. Miki, 2023, International journal of clinical oncology.

Real-world evidence of triplet therapy efficacy in patients with metastatic castration-sensitive prostate cancer: a Japanese multicenter study.

Shunsuke Tsuzuki, Fumihiko Urabe, K. Hata, 2024, Japanese journal of clinical oncology.

Updated systematic review and network meta-analysis of first-line treatments for metastatic renal cell carcinoma with extended follow-up data

K. Mori, P. Rajwa, E. Laukhtina, 2024, Cancer immunology, immunotherapy : CII.

Changes in the treatment landscape of metastatic hormone-sensitive prostate cancer following approval of upfront androgen receptor signaling inhibitors: A multicenter study.

Shunsuke Tsuzuki, K. Mori, Fumihiko Urabe, 2024, International journal of urology : official journal of the Japanese Urological Association.

Adjuvant immunotherapy in patients with renal cell carcinoma and urothelial carcinoma: A systematic review and network meta‐analysis

A. Cimadamore, M. Moschini, B. Pradère, 2023, International journal of urology : official journal of the Japanese Urological Association.